Advertisement
Australia markets close in 1 hour 39 minutes
  • ALL ORDS

    8,403.70
    +39.40 (+0.47%)
     
  • ASX 200

    8,179.10
    +37.00 (+0.45%)
     
  • AUD/USD

    0.6790
    +0.0024 (+0.36%)
     
  • OIL

    70.83
    -0.08 (-0.11%)
     
  • GOLD

    2,584.30
    -14.30 (-0.55%)
     
  • Bitcoin AUD

    91,228.16
    +1,900.80 (+2.13%)
     
  • XRP AUD

    0.86
    +0.01 (+1.01%)
     
  • AUD/EUR

    0.6105
    +0.0026 (+0.42%)
     
  • AUD/NZD

    1.0929
    +0.0037 (+0.34%)
     
  • NZX 50

    12,620.11
    +33.13 (+0.26%)
     
  • NASDAQ

    19,344.49
    -87.90 (-0.45%)
     
  • FTSE

    8,253.68
    -56.18 (-0.68%)
     
  • Dow Jones

    41,503.10
    -103.08 (-0.25%)
     
  • DAX

    18,711.49
    -14.59 (-0.08%)
     
  • Hang Seng

    17,978.83
    +318.81 (+1.81%)
     
  • NIKKEI 225

    37,347.01
    +966.84 (+2.66%)
     

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

Cassava Sciences, Inc.
Cassava Sciences, Inc.

AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.

Event details follow:

Date:

Thursday, August 8th

Time: 

8:30 a.m. Eastern Time

Audio Webcast:

https://www.CassavaSciences.com/company-presentations

Or

 

Audio Webcast:

https://edge.media-server.com/mmc/p/zjvmjjcr

 

 

A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or ESchoen@CassavaSciences.com